February 2016

Intermittent Vismodegib Therapy in Basal Cell Nevus Syndrome

Author Affiliations
  • 1Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia
  • 2Arkansas Skin Cancer Center, Little Rock

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Dermatol. 2016;152(2):223-224. doi:10.1001/jamadermatol.2015.3210

The use of intermittent vismodegib therapy is a promising and sustainable medical alternative to the current mainstream surgical management of basal cell nevus syndrome (BCNS). We report our clinical experience with intermittent vismodegib therapy in 2 patients with BCNS.

Patient 1 is a white man in his 40s, and patient 2 is a white woman in her 50s. Vismodegib therapy was started in both cases because the basal cell carcinoma (BCC) lesions in both patients were becoming more aggressive, were appearing more frequently, and could not be managed as easily with surgical and other nonsurgical treatments.

First Page Preview View Large
First page PDF preview
First page PDF preview